JJV McMurray, DC Wheeler, BV Stefánsson, N Jongs… - Circulation, 2021 - Am Heart Assoc
Background: Dapagliflozin reduces the risk of end-stage renal disease in patients with chronic kidney disease. We examined the relative risk of cardiovascular and renal events in …
JJV McMurray, DC Wheeler, BV Stefánsson, N Jongs… - Heart Failure, 2021 - jacc.org
Objectives The purpose of this paper was to investigate the effects of dapagliflozin in chronic kidney disease (CKD) patients, with and without heart failure (HF). Background Patients with …
HJL Heerspink, N Jongs, GM Chertow… - The lancet Diabetes & …, 2021 - thelancet.com
Background Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified …
Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial effects on renal outcomes mainly in patients with established atherosclerotic cardiovascular …
Abstract Aims/hypothesis In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive …
P Rossing, SE Inzucchi, P Vart, N Jongs… - The Lancet Diabetes & …, 2022 - thelancet.com
Background Chronic kidney disease and heart failure are insulin resistant states associated with a high incidence of diabetes. We assessed the effect of dapagliflozin on new-onset type …
HJL Heerspink, BV Stefánsson… - … England Journal of …, 2020 - Mass Medical Soc
Background Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease …
OBJECTIVE The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular …
DC Wheeler, BV Stefansson, M Batiushin… - Nephrology Dialysis …, 2020 - academic.oup.com
Abstract Background The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the …